Thermo Fisher Announces $3.5 Billion Acquisition of Phadia

Download IconDownload Print IconPrint

Thermo Fisher Announces $3.5 Billion Acquisition of Phadia

Attorney News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Globally connected lawyers counseling clients on complex business and policy matters.
Globally connected lawyers counseling clients on complex business and policy matters.
Focusing on international arbitration and dispute resolution, investigations, financial services enforcement, and IP litigation.
Germany

Longtime WilmerHale client Thermo Fisher Scientific Inc. announced that it has signed a definitive agreement to acquire Phadia-a Sweden-based company that develops, manufactures and markets complete blood-test systems to support the clinical diagnosis and monitoring of allergy and autoimmune diseases-from European private equity firm Cinven. The deal is valued at approximately $3.5 billion in cash and is expected to be completed in the fourth quarter of 2011. Thermo Fisher, a Waltham, Massachusetts-based company, will incorporate Phadia as part of its Specialty Diagnostics business within its Analytical Technologies Segment.

Partner Hal Leibowitz, chair of WilmerHale's Corporate Group, led the team advising Thermo Fisher on the acquisition. Other members of the WilmerHale team included Partners Christian Crones, Jeffrey A. Hermanson, Tim Matthews, Lester Ross, Sven Volcker and Kenneth Zhou; Counsel Cormac O'Daly, Jerry Marr and David Morris; Senior Associates Lisa Arsenidou, Elizabeth Black, Suzy Byron, Stefan Eggert, Aileen Gao and Alison Kapilow; and Associates Philippe Claessens, Christina Frangos, Franziska Irmer, Frederik Rother and Franziska von Kummer. A press release explaining this transaction in greater detail is available on Thermo Fisher's website.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel